Alzamend Neuro, INC DEF 14A proxy statements

Alzamend Neuro, Inc. announced its upcoming annual stockholders' meeting on April 17, 2026, to vote on director elections, auditor ratification, executive compensation, a new stock incentive plan, equity issuances, and a potential reverse stock split.

Alzamend Neuro, Inc. announces its 2026 Annual Meeting of Stockholders to vote on key proposals including a reverse stock split, a new equity incentive plan, and director elections.

Alzamend Neuro issues a second supplement to its proxy statement to correct a typographical error in the virtual meeting link for the 2025 annual stockholder meeting.

Alzamend Neuro files a supplement to its proxy statement to correct an error related to an adjournment proposal inadvertently included on the proxy card.

Alzamend Neuro is holding its 2025 Annual Meeting of Stockholders virtually on April 25, 2025, to vote on key proposals including the election of directors, ratification of auditors, approval of a stock conversion, and a potential reverse stock split.

Alzamend Neuro issues a supplement to its proxy statement, correcting the number of votes entitled to be cast at the upcoming special meeting of stockholders.

Alzamend Neuro is holding a special meeting to seek stockholder approval for the conversion of Series A preferred stock and warrants into common stock to raise up to $25 million and comply with Nasdaq's equity requirements.

Alzamend Neuro is adjourning its annual meeting to seek stockholder approval for the issuance of common stock related to a $6 million securities purchase agreement with Ault Lending, aimed at meeting Nasdaq listing requirements and funding clinical trials.

Alzamend Neuro is holding its 2024 Annual Meeting of Stockholders virtually on April 30, 2024, to vote on key proposals including the election of directors, ratification of the independent auditor, approval of a common stock issuance related to a securities purchase agreement with Ault Lending, and a reverse stock split.